Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

35.41 -0.21 (-0.59%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
28 29 Next >
Amgen's Lumakras/Keytruda/Tecentriq Combo Data Flags Safety Concern
Via Benzinga
These 2 Under-The-Radar Stocks Traded More Than $1B Each Last Month
The month of July saw $37.3 billion in trading volume for stocks that trade on the OTCQK and OTCQB. While some of the stocks that trade over-the-counter are considered penny stocks based on their share... 
Via Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Kiniksa Inks Global License Agreement With Roche For Vixarelimab
Via Benzinga
Poseida Shares Rally As Roche Takes Next Big Step Into Allogeneic CAR-T Field
Via Benzinga
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Genentech’s Subcutaneous Formulation of Tecentriq Demonstrates Positive Phase III Results
From Genentech
Via Business Wire
Blue Chip Stocks In Focus: Roche Holding AG
When examining blue chip stocks, rarely do international companies get brought up. However, there are multiple overseas companies with an established track record of value creation and robust... 
Via Talk Markets
Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Genentech to Present Scientific Progress Across Alzheimer’s Disease Pharmaceutical and Diagnostic Portfolio at 2022 AAIC Annual Meeting
From Genentech
Via Business Wire
Regeneron's Price Target Cut On Dim Prospects For Its Flagship Eye Product
Via Benzinga
Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Benzinga Before The Bell: Baidu Beats Tesla, Finland Sells $47.5M Bitcoins, Tesla's Bitcoin Sale And Other Top Financial Stories Thursday, July 21
CNBC 
Via Benzinga
Roche's Long-Time CEO Passes Baton, Higher Diagnostics, Medicine Sales Lift 1H Sales & Profit
Via Benzinga
Novartis Posts Mixed Q2 Earnings, Expects Improved Earnings At Sandoz
Via Benzinga
Mortgage Financiers & Crypto Securities Reclaim Their Spots As Most Actively Traded Securities On OTC Markets In June
Reflecting the expected conditions of a bear market, many of the world’s indices saw a decrease in price throughout June. 
Via Benzinga
Roche Launches Dual Antigen & Antibody Hepatitis C Diagnostic Test
Via Benzinga
New Two-Year Data Confirm Genentech’s Vabysmo Improves Vision With Fewer Treatments for People With Wet Age-Related Macular Degeneration
From Genentech
Via Business Wire
Why 'Covid Fatigue' Isn't Enough To Keep BioNTech Down; Shares Surge On Upgrade
BioNTech won an upgrade Wednesday. Here's what one analyst expects to drive growth. 
Via Investor's Business Daily
New Data Reinforce Favorable Safety, Efficacy Of Roche's Hemlibra For Hemophilia A
Via Benzinga
The Daily Biotech Pulse: Europe Approves Second Round Of Booster Doses of mRNA COVID-19 Vaccines, Perrigo Seeks Approval For First OTC Birth Control Pill, MacroGenics Closes Head & Cancer Study After Patient Death
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
New Data From Phase III HAVEN 6 Study Reinforce Favorable Safety and Efficacy Profile of Genentech’s Hemlibra (emicizumab-kxwh) in People With Moderate or Mild Hemophilia A
From Genentech
Via Business Wire
Merck Reportedly Eyes $40 Billion Seagen Tie-Up; Will The Deal Save Biotech?
Two major cancer players are reportedly closing in on a massive merger. 
Via Investor's Business Daily
Is Merck Stock A Buy Amid Reports It Could Buy Seagen For $40 Billion?
Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now? 
Via Investor's Business Daily
10 Most Traded OTC Stocks In June: Where Do Danone, Adidas And Grayscale Bitcoin Trust Rank?
The month of June saw $45.2 billion in trading volume for stocks that trade on the OTCQK and OTCQB. While some of the stocks that trade over-the-counter are considered penny stocks based on their share... 
Via Benzinga
Sarepta Reports One Heart Inflammation Case In Duchenne Gene Therapy Trial
Via Benzinga
The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
FDA Grants Priority Review to Genentech’s Mosunetuzumab for People With Relapsed or Refractory Follicular Lymphoma
From Genentech
Via Business Wire
Celldex Therapeutics Skids As It Takes On A Blockbuster Roche, Novartis Drug
The study was in 26 patients with chronic hives that don't respond to antihistamines. 
Via Investor's Business Daily
The OTC Markets' Most-Active Securities Embrace International Operators As Volatility Envelops Markets In May
Reflecting the world’s uncertainty about the U.S. economy, the market’s major indices saw incredible volatility in May. 
Via Benzinga
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
28 29 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.